Page 2 - Les meilleurs doctors traitant la maladie suivante : Léiomyosarkome - TOP -62 des médecins

Le médecin a obtenu son diplôme de la faculté de médecine de l'Université d'Ankara et a complété sa formation en résidence en médecine interne à la faculté de médecine d'Ankara GATA. Spécialisé en oncologie médicale et hématologie, le médecin a complété une bourse clinique aux États-Unis. Pionnier en Turquie, le médecin faisait partie de l'équipe qui a réalisé la première transplantation de moelle osseuse dans le pays. Le médecin a été conférencier invité dans des institutions prestigieuses à Londres et en Suisse. Titulaire du Certificat Européen d'Oncologie Médicale, le médecin est membre fondateur à la fois de la Société Turque d'Oncologie Médicale et du Groupe Oncologique Turc. Le focus clinique inclut les cancers du sein, gastro-intestinaux, pulmonaires, les lymphomes et le myélome.<\/p>

Le Dr Tahsin Ozadli est spécialisé en oncologie médicale, avec une formation approfondie à l'hôpital d'oncologie d'Ankara.

• Se spécialiser dans les cancers du poumon, de l'œsophage et de l'estomac
• Travailler à la clinique d'oncologie médicale de l'hôpital d'oncologie d'Ankara
• Publier des recherches en oncologie – voir le profil Google Scholar

Le professeur Elke Jaeger dirige le service d'oncologie et d'hématologie de Nordwest – nommée l'une des meilleures oncologues d'Allemagne par Focus.

• 39 ans d'expérience spécialisée en oncologie
• Plus de 1 100 procédures réalisées
• Professeur d'oncologie interdisciplinaire
• Membre du comité d'experts de l'EORTC

Le Dr Alemdar se spécialise en oncologie médicale avec une formation approfondie à l'Université d'Akdeniz, une institution de premier plan en Turquie.

• Certifié en oncologie médicale depuis 2018
• Plus de 15 ans d'expérience en médecine interne et en oncologie
• A travaillé à l'hôpital universitaire d'Akdeniz, reconnu pour ses traitements avancés contre le cancer

Le Prof. Dr Ozcan Yildiz possède plus de dix ans de recherche spécialisée et de publications sur des cas oncologiques complexes. Il traite les patients à l'hôpital universitaire Medipol Mega.

• Auteur de nombreuses études sur des tumeurs rares telles que les cancers neuroendocriniens et neuroectodermiques
• Expertise dans la prise en charge des syndromes paranéoplasiques liés au cancer et des présentations inhabituelles
• Expérimenté dans la gestion des effets secondaires complexes des thérapies anticancéreuses avancées
• Membre de réseaux de recherche oncologique professionnelle, contribuant à la littérature médicale

Le Dr Levin dirige le programme des sarcomes pédiatriques au centre médical Sourasky et a étudié à l'Institut orthopédique Rizzoli en Italie, chef de file mondial.

• Plus de 30 ans d'expérience en hématologie et oncologie pédiatriques
• Se spécialiser dans les tumeurs osseuses et les sarcomes des tissus mous chez l'enfant
• Pédiatre principal à l'hôpital pour enfants Dana de Tel Aviv
• Directeur du département d'hématologie-oncologie pédiatrique de Sourasky
• Membre de la Société israélienne d'hématologie et d'oncologie pédiatriques

Le professeur Köstler est un oncologue médical distingué, spécialisé dans les thérapies ciblées, avec plus de 20 ans d'expérience dans les cancers du sein et gynécologiques à la Wiener Privatklinik.

• Professeur associé à l'Université de médecine de Vienne
• Chef adjoint de la division clinique d'oncologie
• Expert en développement de biomarqueurs et en biologie tumorale
• Publier dans de prestigieuses revues internationales d'oncologie

Le professeur Keil est spécialisé dans l'imagerie par coupes et la radiologie interventionnelle, appliquant des techniques avancées telles que l'IRM, le scanner et l'échographie pour une planification précise des diagnostics et des traitements.

• Obtenir son diplôme avec mention de l'Université Julius-Maximilians de Wurtzbourg
• Diriger la clinique de radiologie diagnostique et interventionnelle de l'hôpital universitaire d'Aix-la-Chapelle
• Être actuellement médecin-chef à l'hôpital académique de Solingen
• Être expert en IRM et en scanner pour les pathologies complexes

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Plus de 30 ans d'expérience en immunologie – Le Dr Jaunalksne se spécialise dans la virothérapie, une approche de pointe pour la modulation du système immunitaire.

• Diriger le centre d'immunologie clinique de l'hôpital universitaire clinique Pauls Stradins
• Diplômer de l'Institut médical de Riga avec un internat en médecine interne
• Se concentrer sur les traitements immunologiques innovants

Le Pr. agrégé Nail Paksoy est spécialisé dans le léiomyosarcome à l'hôpital Medipol Bahcelievler, avec une certification de l'ESMO en oncologie médicale.

• Publier des recherches sur la chimiothérapie à haute dose pour le sarcome d'Ewing
• Sous-investigateur dans 8 essais cliniques internationaux pour des cancers avancés
• Bourse de recherche en oncologie médicale à l'Institut d'oncologie de l'Université d'Istanbul
• Membre de l'ESMO avec une expertise dans le traitement des sarcomes

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Dr. Mohamed Mahmoud Abdelhakim is Head of Radiation Oncology at Shefa al Orman Hospital, Luxor. He is Professor of Radiation Oncology at the National Cancer Institute, Cairo University. He previously served as Associate Professor (2015–2020), Lecturer (2010–2015), Assistant Lecturer (2003–2009), and Resident (2000–2003). He also worked as a Specialist at Gharbia Cancer Society.

He treats inpatients and outpatients with breast, soft tissue sarcoma, lymphoma, gynecologic, gastrointestinal, genitourinary, and CNS tumors. His skills include image-guided brachytherapy, IMRT, VMAT, SRS, and SBRT. He performs conventional and CT-based planning and 3D-CRT. He works with cobalt and linear accelerators and electron beam therapy. He provides HDR and LDR intracavitary and interstitial brachytherapy. He also performs stereotactic radiotherapy, total body irradiation, and total skin irradiation.

Member: Egyptian Cancer Society, ESTRO, ESMO.

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.

Dr. Zohar Dotan is Head of the Urology Department at Sheba Medical Center. He is a leading uro-oncologist and a pioneer of robotic and laparoscopic urologic surgery in Israel.

He has authored more than 50 scientific publications. He is a regular speaker at international conferences. He has received awards from the American Association of Clinical Surgery, including recognition for research in prostate cancer treatment.

Leadership and credentials: Head of the Israeli Uro-Oncology Society. Assistant Professor at Tel Aviv University. Member of the Israeli, American, and European Urological Associations. Training: MD from Tel Aviv University and a PhD in Genetics. Urology residency at Sheba Medical Center. Fellowship in uro-oncology and laparoscopic surgery at Memorial Sloan Kettering, New York.